3.97

1.98% -0.08

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $3.97, with a volume of 515.61K. It is down -1.98% in the last 24 hours and down -25.52% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Previous Close:

$4.05

Open:

$3.98

24h Volume:

515.61K

Relative Volume:

0.78

Market Cap:

$244.19M

Revenue:

Net Income/Loss:

$-130.41M

P/E Ratio:

-1.7723

EPS:

-2.24

Net Cash Flow:

$-67.76M

1W Performance:

-0.25%

1M Performance:

-25.52%

6M Performance:

-53.24%

1Y Performance:

-0.50%

1-Day Range:

$3.95

$4.07

1-Week Range:

$3.84

$4.25

52-Week Range:

$3.21

$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (666)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

134

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	3.97	244.81M	0	-130.41M	-67.76M	-2.24
ONC Beigene Ltd Adr	241.43	27.03B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	436.00	112.64B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.335	40.86M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	588.34	64.17B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.06	6.07B	0	-153.72M	-103.81M	-2.00

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

May 24, 2025

Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st

May 24, 2025

May 16, 2025

Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

May 16, 2025

May 15, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World

May 15, 2025

May 10, 2025

Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st

May 10, 2025

May 09, 2025